Ischemic Stroke Drug Pipeline: 59 Assets by Phase

How many ischemic stroke drugs are in each phase of development?

Douglas Insights counts 12 ischemic stroke candidates in Phase III, 20% of the 59 assets in development; Phase II holds 30 and Phase I holds 17.

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each ischemic stroke asset appears in exactly one row. The 327 trials still recruiting or running carry 47% of the 691 registered trials in scope.

Which approved ischemic stroke medicines are still in trials?

5 medicines already on the market are still being tested in ischemic stroke Phase IV trials; Tenecteplase has the most, with 56 registered trials.

Post-approval ischemic stroke trials test new doses, new patient groups and head-to-head comparisons. They set the standard of care that every candidate in development will be measured against, so the paid review profiles each one.

How many ischemic stroke trials are recruiting patients now?

189 ischemic stroke trials are recruiting patients and 114 more have not started recruiting yet, out of 691 interventional trials in scope; together they make up 44% of the trial base.

Terminated, suspended and withdrawn ischemic stroke trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the ischemic stroke pipeline?

Clarion Cells, Inc. leads the ischemic stroke pipeline with 3 candidates; the top 5 sponsors hold 19% of the 59 assets, and 51 sponsors run at least one.

Industry sponsors lead 135 of the 691 ischemic stroke trials (20%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the ischemic stroke pipeline?

Mechanism and drug-type classification for the 59 ischemic stroke candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What ischemic stroke trial readouts are coming next?

19 ischemic stroke candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many ischemic stroke readouts fall in each quarter?

24 ischemic stroke candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 9, due in Q4 2026.

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most ischemic stroke trials?

China hosts the most ischemic stroke trials, with sites in 338 of the 691 studies (49%); trials in scope run in 61 countries in all.

A multinational ischemic stroke trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are ischemic stroke drugs being tested?

81 of the 691 ischemic stroke trials (12%) have a site in the United States, 93 (13%) in Europe and 338 (49%) in China; 19 of the 59 candidates in development are tested in the US.

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational ischemic stroke trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the ischemic stroke pipeline since the last update?

Since 3 Oct 2026, the ischemic stroke pipeline count moved by 0 assets to 59, Phase III moved by 0 and the trial base by 0.

How does Douglas Insights count the ischemic stroke pipeline?

Douglas Insights read 691 interventional trials registered on ClinicalTrials.gov for the conditions "Ischemic Stroke", "Acute Ischemic Stroke" and updated since 3 Oct 2021, then grouped every drug or biologic named in them into 59 unique candidates.

1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

Frequently asked questions about the ischemic stroke pipeline

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Adjacent coverage